Education
About Us
Working with TipRanks
Follow Us
3D Medicines, Inc. (HK:1244)
:1244
1244 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.60 - HK$8.85
Previous CloseN/A
Volume120.00K
Average Volume (3M)906.87K
Market Cap
HK$2.05B
Enterprise ValueHK$25.83M
Total Cash (Recent Filing)HK$840.98M
Total Debt (Recent Filing)HK$237.62M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding258,177,000
10 Day Avg. Volume828,183
30 Day Avg. Volume906,873
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.50Price Target Upside9.40% Upside
Rating ConsensusHold
Number of Analyst Covering0
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.60 and its highest was HK$8.85 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$2.05B.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Aug 29, 2025 which is today.
How were 3D Medicines, Inc.’s earnings last quarter?
Currently, no data Available
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Undervalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
3D Medicines, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$8.50 (9.40% Upside)
HK$8.50 (9.40% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
204.59%
12-Months-Change
Fundamentals
Return on Equity
-21.22%
Trailing 12-Months
Asset Growth
-17.72%
Trailing 12-Months
Company Description
3D Medicines, Inc.
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Transcenta Holding Limited
―
Ownership Overview
―
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---